Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David MacDonald

Showing results (121-130 of 141) with videos related to

Pageof 15
Sort By:
Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphomaDiego Villa, Anupkumar George, John F Seymour, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|September 15, 2020
Evaluation of a preoperative personalized risk communication tool: a prospective before-and-after studyEmily Hladkowicz, David Yachnin, Laura Boland, et al.
Science (New York, N.Y.)|March 13, 2010
Conservation. Elephants, ivory, and tradeSamuel Wasser, Joyce Poole, Phyllis Lee, et al.
Blood|May 12, 2016
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphomaSarit E Assouline, Torsten Holm Nielsen, Stephen Yu, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Scientific Data|January 19, 2022
Landscape Dynamics (landDX) an open-access spatial-temporal database for the Kenya-Tanzania borderlandsPeter Tyrrell, Irene Amoke, Koen Betjes, et al.
The Lancet. Oncology|October 31, 2024
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practiceSpyridon Bakas, Philipp Vollmuth, Norbert Galldiks, et al.
The Lancet. Oncology|October 31, 2024
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancementsJavier E Villanueva-Meyer, Spyridon Bakas, Pallavi Tiwari, et al.
Pageof 15

Showing results (121-130 of 141) with videos related to

Sort By:
Pageof 15
Future Oncology (London, England)|February 23, 2023
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemiaChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 4, 2021
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE StudyChristian Buske, Alessandra Tedeschi, Judith Trotman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphomaDiego Villa, Anupkumar George, John F Seymour, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|September 15, 2020
Evaluation of a preoperative personalized risk communication tool: a prospective before-and-after studyEmily Hladkowicz, David Yachnin, Laura Boland, et al.
Science (New York, N.Y.)|March 13, 2010
Conservation. Elephants, ivory, and tradeSamuel Wasser, Joyce Poole, Phyllis Lee, et al.
Blood|May 12, 2016
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphomaSarit E Assouline, Torsten Holm Nielsen, Stephen Yu, et al.
The Lancet. Oncology|December 14, 2016
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialMeletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, et al.
Scientific Data|January 19, 2022
Landscape Dynamics (landDX) an open-access spatial-temporal database for the Kenya-Tanzania borderlandsPeter Tyrrell, Irene Amoke, Koen Betjes, et al.
The Lancet. Oncology|October 31, 2024
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practiceSpyridon Bakas, Philipp Vollmuth, Norbert Galldiks, et al.
The Lancet. Oncology|October 31, 2024
Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancementsJavier E Villanueva-Meyer, Spyridon Bakas, Pallavi Tiwari, et al.
Pageof 15